Related Experiment Video

Updated: Aug 8, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.3K

Mitotic Kinase Inhibitors as Therapeutic Interventions for Prostate Cancer: Evidence from In Vitro Studies

Aadil Javed1, Gülseren Özduman1, Sevda Altun1

  • 1Department of Bioengineering, Faculty of Engineering, Cancer Biology Laboratory, Ege University, Bornova, Izmir, Turkey.

Endocrine, Metabolic & Immune Disorders Drug Targets
|March 5, 2023
PubMed

Insights

Mitotic kinases like PLK1 are crucial for cell division and are often overexpressed in prostate cancer. Targeting these kinases with small molecule inhibitors shows promise for new cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Prostate cancer is a prevalent malignancy globally, driven by genetic alterations leading to uncontrolled cell growth and metastasis.
  • Current treatments include hormonal and chemotherapeutic agents, effective primarily in early-stage disease.
  • Mitotic kinases regulate cell division, ensuring genomic integrity, and are frequently overexpressed in various cancers.

Purpose of the Study:

  • To review the functions of key mitotic kinases, including Polo-Like-Kinase 1 (PLK1), Aurora kinases, and Cyclin-Dependent-Kinase 1 (CDK1).
  • To explore the therapeutic potential of small molecule inhibitors targeting these kinases in prostate cancer.
  • To elucidate the cellular and molecular mechanisms of action for these inhibitors in prostate cancer cells.

Main Methods:

  • Review of cell culture studies detailing mitotic kinase functions.
  • Analysis of pre-clinical studies on small molecule inhibitors targeting mitotic kinases.
  • Focus on research specifically conducted on prostate-origin cells.

Main Results:

  • Mitotic kinases are essential regulators of cell cycle progression and mitosis.
  • Overexpression of these kinases is common in prostate cancer.
  • Small molecule inhibitors targeting mitotic kinases demonstrate potential in pre-clinical prostate cancer models.

Conclusions:

  • Mitotic kinases represent a promising therapeutic target for prostate cancer.
  • Targeted inhibition of these kinases may offer novel treatment strategies.
  • Further research into small molecule inhibitors is crucial for advancing prostate cancer therapy.
Keywords:
Prostatecancercell cyclecell lines.inhibitorskinasesmitosis

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K